GeromiRs Are Downregulated in the Tumor Microenvironment during Colon Cancer Colonization of the Liver in a Murine Metastasis Model.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
01 May 2021
Historique:
received: 25 03 2021
revised: 23 04 2021
accepted: 27 04 2021
entrez: 2 6 2021
pubmed: 3 6 2021
medline: 29 6 2021
Statut: epublish

Résumé

Cancer is a phenomenon broadly related to ageing in various ways such as cell cycle deregulation, metabolic defects or telomerases dysfunction as principal processes. Although the tumor cell is the main actor in cancer progression, it is not the only element of the disease. Cells and the matrix surrounding the tumor, called the tumor microenvironment (TME), play key roles in cancer progression. Phenotypic changes of the TME are indispensable for disease progression and a few of these transformations are produced by epigenetic changes including miRNA dysregulation. In this study, we found that a specific group of miRNAs in the liver TME produced by colon cancer called geromiRs, which are miRNAs related to the ageing process, are significantly downregulated. The three principal cell types involved in the liver TME, namely, liver sinusoidal endothelial cells, hepatic stellate (Ito) cells and Kupffer cells, were isolated from a murine hepatic metastasis model, and the miRNA and gene expression profiles were studied. From the 115 geromiRs and their associated hallmarks of aging, which we compiled from the literature, 75 were represented in the used microarrays, 26 out of them were downregulated in the TME cells during colon cancer colonization of the liver, and none of them were upregulated. The histone modification hallmark of the downregulated geromiRs is significantly enriched with the geromiRs

Identifiants

pubmed: 34062897
pii: ijms22094819
doi: 10.3390/ijms22094819
pmc: PMC8124834
pii:
doi:

Substances chimiques

MicroRNAs 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Horizon 2020 Framework Programme
ID : JTC-2 2017
Organisme : Instituto de Salud Carlos III
ID : AC17/00012
Organisme : Gobierno Vasco Departamento de Salud
ID : No. 2020333039 and 2020333001.
Organisme : Diputación Foral de Gipuzkoa
ID : DFG109/20
Organisme : Horizon 2020 Framework Programme
ID : 899417

Références

Neurochem Int. 2014 Nov;77:33-9
pubmed: 24681158
Mol Cancer Res. 2008 Dec;6(12):1830-40
pubmed: 19074828
Liver Res. 2020 Jun;4(2):74-80
pubmed: 33005474
Oncogene. 2004 Apr 12;23(16):2919-33
pubmed: 15077154
Cancer Cell. 2019 Oct 14;36(4):418-430.e6
pubmed: 31588021
Nucleic Acids Res. 2020 Jul 2;48(W1):W244-W251
pubmed: 32484539
Cell Physiol Biochem. 2018;51(5):2111-2122
pubmed: 30522100
Oncol Lett. 2018 Nov;16(5):6598-6602
pubmed: 30333890
Theranostics. 2020 Jul 9;10(19):8494-8512
pubmed: 32754259
Mol Cell Biochem. 2013 Jan;372(1-2):35-45
pubmed: 22956424
Growth Factors. 2001;19(2):87-100
pubmed: 11769974
Tumour Biol. 2016 Jun;37(6):7095-108
pubmed: 27039398
Clin Exp Metastasis. 1999;17(8):669-76
pubmed: 10919712
PLoS One. 2020 Jun 10;15(6):e0233782
pubmed: 32520974
FASEB J. 2019 Feb;33(2):2314-2326
pubmed: 30252536
Oncol Rep. 2020 Jun;43(6):1906-1914
pubmed: 32186774
Cancers (Basel). 2020 Aug 22;12(9):
pubmed: 32842712
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
Mol Oncol. 2017 Dec;11(12):1673-1686
pubmed: 29024380
Genes (Basel). 2014 Aug 20;5(3):656-70
pubmed: 25140888
Cancer Res. 2007 May 1;67(9):4138-48
pubmed: 17483324
Cancer Biol Ther. 2018;19(10):858-868
pubmed: 29580128
Biochem Biophys Res Commun. 2018 Oct 12;504(4):820-826
pubmed: 30219228
Dev Genet. 1996;18(2):173-9
pubmed: 8934879
CNS Neurol Disord Drug Targets. 2017;16(9):1000-1009
pubmed: 28782488
Adv Anat Pathol. 2019 Jan;26(1):69-74
pubmed: 30339548
Cancer Res. 2006 Feb 1;66(3):1277-81
pubmed: 16452179
Adv Clin Exp Med. 2017 Aug;26(5):865-874
pubmed: 29068585
Aging (Albany NY). 2020 Oct 28;12(20):20835-20861
pubmed: 33125346
Adv Exp Med Biol. 2015;887:213-30
pubmed: 26662993
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Biochem Biophys Res Commun. 2000 Jul 5;273(2):793-8
pubmed: 10873683
PLoS One. 2012;7(10):e47863
pubmed: 23110115
Nat Rev Gastroenterol Hepatol. 2017 Jul;14(7):397-411
pubmed: 28487545
Glia. 2019 Jan;67(1):101-112
pubmed: 30294880
Neuropsychopharmacology. 2009 May;34(6):1395-405
pubmed: 18704095
Front Oncol. 2020 Oct 02;10:553714
pubmed: 33123467
J Transl Med. 2013 Oct 30;11:275
pubmed: 24171926
Int J Cancer. 2018 Aug 1;143(3):709-719
pubmed: 29492958
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94
pubmed: 29115304
Int J Mol Sci. 2012;13(2):1347-79
pubmed: 22408395
Science. 1990 Jan 19;247(4940):322-4
pubmed: 2296722
Gastroenterology. 2009 Dec;137(6):2136-45.e1-7
pubmed: 19747919
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
J Invest Dermatol. 2014 Feb;134(2):470-480
pubmed: 23938462
J Pathol. 1997 Mar;181(3):294-300
pubmed: 9155715
J Proteome Res. 2012 Sep 7;11(9):4744-54
pubmed: 22897626
Hepatology. 1994 Aug;20(2):494-514
pubmed: 8045510
Mech Ageing Dev. 2017 Dec;168:10-19
pubmed: 28502819
Oncotarget. 2016 May 31;7(22):33246-56
pubmed: 27119349
J Cell Physiol. 2019 May;234(5):5451-5465
pubmed: 30471116
J Cell Physiol. 2019 May;234(5):5496-5506
pubmed: 30246332
Cell Death Differ. 2010 Feb;17(2):215-20
pubmed: 19498445
Front Immunol. 2018 Jan 05;8:1931
pubmed: 29354134
Mol Cancer Ther. 2014 Jul;13(7):1942-51
pubmed: 24785257
Adv Biol Regul. 2015 Jan;57:1-9
pubmed: 25294678
Mol Cell Biochem. 2014 Mar;388(1-2):11-23
pubmed: 24242045
Cell. 2000 Aug 18;102(4):407-10
pubmed: 10966103
Onco Targets Ther. 2014 Feb 20;7:325-32
pubmed: 24570594
Exp Cell Res. 1961 Dec;25:585-621
pubmed: 13905658
Theranostics. 2014 Sep 19;4(12):1193-208
pubmed: 25285168
J Intern Med. 2008 Feb;263(2):128-41
pubmed: 18226091
Nature. 1990 May 31;345(6274):458-60
pubmed: 2342578

Auteurs

Daniela Gerovska (D)

Computational Biology and Systems Biomedicine Group, Biodonostia Health Research Institute, C/Doctor Beguiristain s/n, 20014 San Sebastián, Spain.
Computational Biomedicine Data Analysis Platform, Biodonostia Health Research Institute, C/Doctor Beguiristain s/n, 20014 San Sebastián, Spain.

Patricia Garcia-Gallastegi (P)

Department of Cell Biology and Histology, Faculty of Medicine and Nursing, University of Basque Country (UPV/EHU), 48940 Leioa, Spain.

Olatz Crende (O)

Department of Cell Biology and Histology, Faculty of Medicine and Nursing, University of Basque Country (UPV/EHU), 48940 Leioa, Spain.

Joana Márquez (J)

Department of Cell Biology and Histology, Faculty of Medicine and Nursing, University of Basque Country (UPV/EHU), 48940 Leioa, Spain.

Gorka Larrinaga (G)

Department of Nursing I, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.
Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.
BioCruces Health Research Institute, 48903 Barakaldo, Spain.

Maite Unzurrunzaga (M)

Centro Salud Legazpi OSI Goierri-Urola Garaia-Osakidetza, 20230 Legazpia, Spain.

Marcos J Araúzo-Bravo (MJ)

Computational Biology and Systems Biomedicine Group, Biodonostia Health Research Institute, C/Doctor Beguiristain s/n, 20014 San Sebastián, Spain.
Computational Biomedicine Data Analysis Platform, Biodonostia Health Research Institute, C/Doctor Beguiristain s/n, 20014 San Sebastián, Spain.
IKERBASQUE, Basque Foundation for Science, C/María Díaz Harokoa 3, 48013 Bilbao, Spain.
CIBER of Frailty and Healthy Aging (CIBERfes), 28029 Madrid, Spain.
TransBioNet Thematic Network of Excellence for Transitional Bioinformatics, Barcelona Supercomputing Center, 08034 Barcelona, Spain.
Computational Biology and Bioinformatics Group, Max Planck Institute for Molecular Biomedicine, Röntgenstr. 20, 48149 Münster, Germany.

Iker Badiola (I)

Department of Cell Biology and Histology, Faculty of Medicine and Nursing, University of Basque Country (UPV/EHU), 48940 Leioa, Spain.
Nanokide Therapeutics SL, Zitek Ed, Rectorado Bajo, Bº Sarriena sn, 48940 Leioa, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH